137 related articles for article (PubMed ID: 8477064)
1. A comparative study of CHOP versus MEVP (mitoxantrone, etoposide, vindesine, prednisolone) therapy for intermediate-grade and high-grade non-Hodgkin's lymphoma: a prospective randomized study.
Takagi T; Sampi K; Sawada U; Sakai C; Oguro M
Int J Hematol; 1993 Jan; 57(1):67-71. PubMed ID: 8477064
[TBL] [Abstract][Full Text] [Related]
2. [Alternating CHOP-MEVP chemotherapy for advanced-stage, intermediate- and high-grade non-Hodgkin's lymphomas].
Takagi T; Sakai C; Oguro M
Gan To Kagaku Ryoho; 1993 Nov; 20(14):2191-4. PubMed ID: 8239684
[TBL] [Abstract][Full Text] [Related]
3. [Comparison of chemotherapy CHOP vs. CHOP/VIA in the treatment of aggressive non-Hodgkin's lymphoma: a randomized multicenter study of 132 patients. The PETHEMA group. Program for Study and Therapeutics of malignant hemopathies. Spanish Association of Hematology and Hemotherapy].
López-Guillermo A; García-Conde J; Alvarez-Carmona AM; León P; Maldonado J; Alcalá A; Zubizarreta A; Sancho-Tello R; Carbonell F; Contreras E; Besses C; Hernando A; Fontanillas M; Montserrat E
Med Clin (Barc); 1998 May; 110(16):601-4. PubMed ID: 9656196
[TBL] [Abstract][Full Text] [Related]
4. [Comparing CHOP, CHOP+HD-MTX,and BFM-90 regimens in the survival rate of children and adolescents with B cell non-Hodgkin's lymphoma].
Sun XF; Su YS; Liu DG; Jiang WQ; He YJ; Lin TY; Huang HQ; Zhang L; Xia ZJ; Li YH; Zhou ZM; Chen XQ; Xia Y; Zhen ZJ; Guan ZZ
Ai Zheng; 2004 Aug; 23(8):933-8. PubMed ID: 15301718
[TBL] [Abstract][Full Text] [Related]
5. Impact of three courses of intensified CHOP prior to high-dose sequential therapy followed by autologous stem-cell transplantation as first-line treatment in poor-risk, aggressive non-hodgkin's lymphoma: comparative analysis of Dutch-Belgian Hemato-Oncology Cooperative Group Studies 27 and 40.
van Imhoff GW; van der Holt B; Mackenzie MA; Van't Veer MB; Wijermans PW; Ossenkoppele GJ; Schouten HC; Sonneveld P; Steijaert MM; Kluin PM; Kluin-Nelemans HC; Verdonck LF;
J Clin Oncol; 2005 Jun; 23(16):3793-801. PubMed ID: 15809447
[TBL] [Abstract][Full Text] [Related]
6. [Weekly CHOP chemotherapy in the treatment of intermediate-grade non-Hodgkin's lymphomas--cooperative group study by seven institutes].
Kobayashi M; Sao H; Mizuta S; Kamiya O; Ohara K; Nagata K; Takeyama H; Watanabe E; Yamada H; Mizuno H
Rinsho Ketsueki; 1990 Oct; 31(10):1656-63. PubMed ID: 2255056
[TBL] [Abstract][Full Text] [Related]
7. [Treatment of aggressive non-Hodgkin's lymphoma with the ProMACE- CytaBOM protocol].
Mihaljević B; Jancić-Nedeljkov R; Sretenović M; Milivojević G; Janković S; Petrović M
Srp Arh Celok Lek; 1998; 126(9-10):345-8. PubMed ID: 9863405
[TBL] [Abstract][Full Text] [Related]
8. Long-term outcome of localized high-grade non-Hodgkin's lymphoma treated with high dose CHOP regimen and involved field radiotherapy: results of a GOELAMS study.
Bernard M; Cartron G; Rachieru P; LeMevel A; Branger B; Le Maignan C; Berthou C; Ghandour C; Delwail V; Milpied N; Cassasus P; Celigny PS; Guyotat D; Lamy T; Desablens B;
Haematologica; 2005 Jun; 90(6):802-9. PubMed ID: 15951293
[TBL] [Abstract][Full Text] [Related]
9. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
10. A phase II multicenter trial of high-dose sequential chemotherapy and peripheral blood stem cell transplantation as initial therapy for patients with high-risk non-Hodgkin's lymphoma.
Schenkein DP; Roitman D; Miller KB; Morelli J; Stadtmauer E; Pecora AL; Cassileth P; Fernandez H; Cooper BW; Kutteh L; Lazarus HM
Biol Blood Marrow Transplant; 1997 Oct; 3(4):210-6. PubMed ID: 9360783
[TBL] [Abstract][Full Text] [Related]
11. Dose-intense chemotherapy every 2 weeks with dose-intense cyclophosphamide, doxorubicin, vincristine, and prednisone may improve survival in intermediate- and high-grade lymphoma: a phase II study of the Southwest Oncology Group (SWOG 9349).
Blayney DW; LeBlanc ML; Grogan T; Gaynor ER; Chapman RA; Spiridonidis CH; Taylor SA; Bearman SI; Miller TP; Fisher RI;
J Clin Oncol; 2003 Jul; 21(13):2466-73. PubMed ID: 12829664
[TBL] [Abstract][Full Text] [Related]
12. A variant of ProMACE-CytaBOM chemotherapy for non-Hodgkin's lymphoma with threefold higher drug dose size but identical cumulative dose intensity. A pilot study of the Italian lymphoma study group (GISL).
Gobbi PG; Ghirardelli ML; Avanzini P; Baldini L; Quarta G; Stelitano C; Broglia C; Loni C; Silingardi V; Ascari E
Haematologica; 2000 Mar; 85(3):263-8. PubMed ID: 10702814
[TBL] [Abstract][Full Text] [Related]
13. [Different chemotherapy protocols for intermediate and high grade malignant non-Hodgkin's lymphoma].
Wang A; Luo Y; Wang Z
Zhonghua Zhong Liu Za Zhi; 1997 May; 19(3):215-7. PubMed ID: 10920901
[TBL] [Abstract][Full Text] [Related]
14. Combined chemotherapy with carmustine, doxorubicin, etoposide, vincristine, and cyclophosphamide plus mitoxantrone, cytarabine and methotrexate with citrovorum factor for the treatment of aggressive non-Hodgkin lymphoma: a long-term follow-up study.
Rigacci L; Carrai V; Nassi L; Alterini R; Longo G; Bernardi F; Bosi A
Cancer; 2005 Mar; 103(5):970-7. PubMed ID: 15666323
[TBL] [Abstract][Full Text] [Related]
15. Prednimustine, mitoxantrone (PmM) vs cyclophosphamide, vincristine, prednisone (COP) for the treatment of advanced low-grade non-Hodgkin's lymphoma. German Low-Grade Lymphoma Study Group.
Unterhalt M; Herrmann R; Tiemann M; Parwaresch R; Stein H; Trümper L; Nahler M; Reuss-Borst M; Tirier C; Neubauer A; Freund M; Kreuser ED; Dietzfelbinger H; Bodenstein H; Engert A; Stauder R; Eimermacher H; Landys K; Hiddemann W
Leukemia; 1996 May; 10(5):836-43. PubMed ID: 8656680
[TBL] [Abstract][Full Text] [Related]
16. A phase I trial to assess the value of recombinant human granulocyte colony stimulating factor (R-MeTHuG-CSF, filgrastim) in accelerating the dose rate of chemotherapy for intermediate and high-grade non-Hodgkin's lymphoma (NHL). The Central Lymphoma Group.
Smith GM; Child JA; Cullen MH; Bailey NP; Woodruffe CM; Fletcher J; Earl H; Barnard D
Hematol Oncol; 1996 Dec; 14(4):193-201. PubMed ID: 9267465
[TBL] [Abstract][Full Text] [Related]
17. [Comparative study of 1st generation versus 2d generation (CAVPE) combinations in intermediate and high-grade lymphomas].
Pavlovsky S; Milone G; Somoza N; Corrado C; Magnasco H; Cerutti I; Saslavsky J; Fernández I; Bruno S
Sangre (Barc); 1993 Feb; 38(1):17-23. PubMed ID: 8470032
[TBL] [Abstract][Full Text] [Related]
18. Localized stage I-IE aggressive non-Hodgkin's lymphoma (NHL): results of prospective study with multimodality therapeutic approach.
De Sanctis V; Martelli M; Anticoli AP; Caronna R; Chirletti P; Giovannini M; Santarelli M; Enrici RM; Mandelli F
Anticancer Res; 2001; 21(6A):4169-72. PubMed ID: 11911313
[TBL] [Abstract][Full Text] [Related]
19. [A comparative study of mitoxantrone and adriamycin in patients with non-Hodgkin's lymphoma: a preliminary result].
Kimura I; Ohnoshi T; Masaoka T; Sampi K; Namba K
Gan To Kagaku Ryoho; 1986 Sep; 13(9):2813-9. PubMed ID: 3530138
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of ABMT in comparison with CHOP chemotherapy in patients with intermediate- and high-grade malignant non-Hodgkin's lymphoma (NHL).
Uyl-de Groot CA; Hagenbeek A; Verdonck LF; Löwenberg B; Rutten FF
Bone Marrow Transplant; 1995 Sep; 16(3):463-70. PubMed ID: 8535321
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
